Postprandial Plasma Fructose Level Is Associated with Retinopathy in Patients with Type 2 Diabetes

Metabolism: Clinical and Experimental

Volumn 53, Issue 5, 2004, Pages 583-588

  Kawasaki, Takahiro ^a   Ogata, Nobuyuki ^b   Akanuma, Hiroshi ^b   Sakai, Tadashi ^b   Watanabe, Hiroyuki ^b   Ichiyanagi, Kaoru ^b   Yamanouchi, Toshikazu ^b  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ANHYDROSORBITOL; ALBUMIN; FRUCTOSE; GLUCOSE; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; FEMALE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA;

EID: 2342521358     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2003.12.007     Document Type: Article

References (20)

1. McPherson JD, Shilton BH, Walton DJ: Role of fructose in glycation and cross-linking of proteins. Biochemistry 27:1901-1907, 1988
2. Hamada Y, Nakamura J, Naruse K, et al: Epalrestat, an aldose reductase inhibitor, reduces the levels of Nepsilon-(carboxymethyl) lysine protein adducts and their precursors in erythrocytes from diabetes patients. Diabetes Care 23:1539-1544, 2000
3. Kashiwagi A, Obata T, Suzaki M, et al: Increase in cardiac muscle fructose content in streptozotocin-induced diabetic rats. Metabolism 41:1041-1046, 1992
4. Poulson R, Boot-Handford RP, Health H: The effects of long-term treatment of streptozotocin-diabetic-rats with an aldose reductase inhibitor. Exp Eye Res 37:507-515, 1983.
5. Tomlinson DR, Townsend J, Fretten P: Prevention of defective axonal transport in streptozotocin-diabetic rats by treatment with "Statil" (ICI 1228436), an aldose reductase inhibitor. Diabetes 34:970-972, 1985
6. Kawasaki T, Akanuma H, Yamanouchi T: Increased fructose concentrations in blood and urine in patients with diabetes. Diabetes Care 25:353-357, 2002
7. Hayward LD, Angyal SJ: A symmetry rule for the circular dichroism of reducing sugars, and the proportion of carbonyl forms in aqueous solutions thereof. Carbohydr Res 53:13-20, 1977
8. Kruszynska YT, Meyer-Alber A, Wellen N, et al: Energy expenditure and substrate metabolism after oral fructose in cirrhosis. J Hepatol 19:241-251, 1993
9. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
10. UK Prospective Diabetes Study Group: Intensive blood-glucose control, with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
11. Klein R, Klein BEK, Moss SE, et al: The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. Ophthalmology 105:1801-1815, 1998
12. Porta M, Sjoelie AK, Chaturvedi N, et al: Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia 44:2203-2209, 2001
13. Lövestam-Adrian M, Agardh CD, Torffvit O, et al: Diabetic retinopathy, visual acuity, and medical risk indicators-A continuous 10-year follow-up study in type 1 diabetic patients under routine care. J Diabetes Complications 15:287-294, 2001
14. Voutilainen-Kaunisto RM, Teräsvirta ME, Uusitupa MIJ, et al: Occurrence and predictors of retinopathy and visual acuity in type 2 diabetic patients and control subjects. 10-year follow-up from the diagnosis. J Diabetes Complications 15:24-33, 2001
15. Mayes PA: Intermediary metabolism of fructose. Am J Clin Nutr 58:754S-765S, 1993
16. Scriver CR, Beaudet AL, Sly WS, et al: The Metabolic and Molecular Bases of Inherited Disease (ed 7), vol 1. New York, NY, McGraw-Hill, 1995, pp 905-934
17. Kawasaki T, Ogata N, Akanuma H, et al: Plasma fructose significantly increased after the oral glucose loading in patients with type 2 diabetes. Diabetes 52:A549, 2003 (abstr)
18. Mooy JM, Grootenhuis PA, de Vries H, et al: Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: The Hoom Study. Diabetologia 39:298-305, 1996
19. Ko GTC, Chan JCN, Woo J, et al: The reproducibility and usefulness of the oral glucose tolerance test in screening for diabetes and other cardiovascular risk factor. Ann Clin Biochem 35:62-67, 1998
20. Agardh E, Tallroth G, Bauer B, et al: Retinopathy and nephropathy in insulin-dependent diabetics: An inconsistent relationship? Diabet Med 4:248-250, 1987